Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma.

ABSTRACT:

Purpose

Brentuximab vedotin (BV)-based combinations have shown promising results in patients with relapsed or refractory Hodgkin's lymphoma (RRHL) in Western countries. We conducted a phase II study to further define the role of BV-based salvage therapy in transplant-eligible patients with RRHL in Korea.

Methods

Transplant-eligible patients with RRHL were recruited to receive two cycles of BV (1.8 mg/kg) plus DHAP (cisplatin 100 mg/m², cytarabine 2 g/m², and dexamethasone 40 mg). Autologous stem cells were collected from non-progressive patients who received one more cycle of BV-DHAP. After three cycles, the responding patients underwent autologous stem cell transplantation (ASCT). The primary endpoint was a complete metabolic response (CMR) rate after

SUBMITTER: Yi JH 

PROVIDER: S-EPMC12638574 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature